Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28471474
DOI
10.1002/jcp.25987
Knihovny.cz E-zdroje
- Klíčová slova
- Sorafenib, fasting, hepatic stellate cells, hepatocellular carcinoma,
- MeSH
- antitumorózní látky farmakologie MeSH
- buňky Hep G2 MeSH
- časové faktory MeSH
- experimentální cirhóza jater metabolismus patologie MeSH
- fenylmočovinové sloučeniny farmakologie MeSH
- glukosa metabolismus MeSH
- hepatocelulární karcinom farmakoterapie genetika metabolismus patologie MeSH
- jaterní hvězdicovité buňky účinky léků metabolismus patologie MeSH
- lidé MeSH
- lipopolysacharidy farmakologie MeSH
- myši inbrední C57BL MeSH
- nádory jater farmakoterapie genetika metabolismus patologie MeSH
- nealkoholová steatóza jater metabolismus patologie MeSH
- niacinamid analogy a deriváty farmakologie MeSH
- omezení příjmu potravy metabolismus MeSH
- proliferace buněk účinky léků MeSH
- regulace genové exprese u nádorů účinky léků MeSH
- sorafenib MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antitumorózní látky MeSH
- fenylmočovinové sloučeniny MeSH
- glukosa MeSH
- lipopolysacharidy MeSH
- niacinamid MeSH
- sorafenib MeSH
Hepatocellular carcinoma (HCC) has a poor outcome. Most HCCs develop in the context of liver fibrosis and cirrhosis caused by chronic inflammation. Short-term fasting approaches enhance the activity of chemotherapy in preclinical cancer models, other than HCC. Multi-tyrosine kinase inhibitor Sorafenib is the mainstay of treatment in HCC. However, its benefit is frequently short-lived. Whether fasting can alleviate liver fibrosis and whether combining fasting with Sorafenib is beneficial remains unknown. A 24 hr fasting (2% serum, 0.1% glucose)-induced changes on human hepatic stellate cells (HSC) LX-2 proliferation/viability/cell cycle were assessed by MTT and flow cytometry. Expression of lypolysaccharide (LPS)-induced activation markers (vimentin, αSMA) was evaluated by qPCR and immunoblotting. Liver fibrosis and inflammation were evaluated in a mouse model of steatohepatitis exposed to cycles of fasting, by histological and biochemical analyses. A 24 hr fasting-induced changes were also analyzed on the proliferation/viability/glucose uptake of human HCC cells exposed to Sorafenib. An expression panel of genes involved in survival, inflammation, and metabolism was examined by qPCR in HCC cells exposed to fasting and/or Sorafenib. Fasting decreased the proliferation and the activation of HSC. Repeated cycles of short term starvation were safe in mice but did not improve fibrosis. Fasting synergized with Sorafenib in hampering HCC cell growth and glucose uptake. Finally, fasting normalized the expression levels of genes which are commonly altered by Sorafenib in HCC cells. Fasting or fasting-mimicking diet diets should be evaluated in preclinical studies as a mean to potentiate the activity of Sorafenib in clinical use.
Center for Translational Medicine St Anne's University Hospital Brno Czech Republic
Department of Biology Masaryk University Brno Czech Republic
Department of Medicine Surgery and Neuroscience University of Siena Siena Italy
Euro Mediterranean Institute of Science and Technology Palermo Italy
Gastroenterology Unit IRCCS Casa Sollievo della Sofferenza Hospital San Giovanni Rotondo Italy
Institute for Liver and Digestive Health University College London Royal Free Hospital London UK
Citace poskytuje Crossref.org